1. We studied the acute effects of intranasal and subcutaneous calcitonin in 40 patients with active Paget's disease of bone. Patients received a single dose of either 400 units of calcitonin delivered as a nasal spray, or 1, 10 or 100 units of subcutaneous calcitonin, or placebo.
INTRODUCTION
Calcitonin is used in the management of several disorders associated with an increased resorption of bone. These include Paget's disease of bone [l, 21, postmenopausal osteoporosis [3] , algodystrophy [4] and hypercalcaemia due to malignancy [5, 61. There are several problems, however, regarding the use of calcitonin. It is rapidly Correspondence: Dr J. A. Kanis degraded by gastric secretions, and for this reason is usually administered parenterally [5] . In addition, unpleasant side-effects have been reported in up to 77% of patients [7, 81 , and although usually mild and transient, they may be severe enough to stop treatment in up to 15% of patients [7, 8] . This has limited the use of calcitonin for long-term treatment, and has prompted the search for novel routes of administration without these problems.
There is now clear evidence that calcitonin is absorbed across the nasal mucosa [9-121, but there are conflicting data on its efficacy . Difficulties with the assay of calcitonin when low doses are given and the paucity of dose-response data for the parenteral route has made it difficult to assess the bioequivalence of intranasal calcitonin. For this reason we studied the acute hypocalcaemic response to administered calcitonin. Since the fall in serum calcium induced by calcitonin is primarily due to its inhibitory effects on osteoclasts [18] , and the degree of hypocalcaemia is proporti.onal to the rate of bone turnover [19] , we chose to investigate this in patients with Paget's disease of bone.
MATERIALS AND METHODS
We studied 40 patients with active Paget's disease of bone. These patients were divided into five treatment groups, which were matched for disease activity. Nine patients received, sequentially and in a random order, 1, 10 and 100 units of salmon calcitonin subcutaneously (Calsynar; Rorer). These tests were separated in time by at least 2 weeks. For the 1 and 10 unit tests, standard salmon calcitonin solution was diluted with saline (150 mmol/l NaCI) containing albumin, to minimize its adsorption to the plastic syringe. Nine further patients, matched for disease activity ( k lo%), were given a subcutaneous injection of saline. These two groups were compared with a third group of randomly selected 22 patients, who received 400 units of intranasal salmon calcitonin (SMC 20-051; Sandoz), administered as a nasal spray of 200 units into each nostril. 
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All patients were admitted to a Metabolic Unit for the period of the test. After an overnight fast and after voiding the bladder, the urine produced over the subsequent hour was collected and saved. Halfway through this period a venous blood sample was taken for serum estimations. At the end of the first urine collection, calcitonin or saline was administered to the patients, and hourly urine and blood collections were made for the next G h. The patients remained fasting throughout the 6 h of the test, but were allowed to drink distilled water. The urine samples were taken into acidified bottles and stored at 4°C until analysis.
Serum was analysed for calcium, phosphate, alkaline phosphatase, creatinine, hepatic transaminases, urea and electrolytes using the Technicon SMAC. Serum calcium values were adjusted for fluctuations in serum albumin (corrected to an albumin level of 42 g/l).
The urine was assayed for phosphate, hydroxyproline and creatinine by automated methods [20] . Urinary excretion of hydroxyproline was expressed as a molar ratio to creatinine excretion.
The significance of differences between treatments was assessed using one-way analysis of variance and Student's f-test for unpaired data. Changes in biochemical values during each treatment were studied using the r-test for paired observations. In the case of hydroxyproline and alkaline phosphatase, statistical comparisons were made on log-transformed values, but were antilogged for presentation. Results are expressed as means k SEM, unless otherwise indicated.
The study had the prior approval of the local Ethical Committee and all patients gave informed consent before enrollment.
RESULTS
Before the start of this study there were no significant differences between the groups in any of the measured variables. In particular, the prevailing rates of bone turnover, as judged by the urinary excretion of hydroxyproline and the serum activity of alkaline phosphatase, were well matched in the placebo and each of the test groups (Table 1) .
Changes in serum calcium
A decrease in serum calcium was observed after the injection of 100 units of subcutaneous calcitonin, which was evident by the end of the first hour (P= 0.002) and maximal from 4 to G h (Fig. 1 ). The summated change in Table 1 . Initial values of serum alkaline phosphatase activity and the urinary hydroxyproline/creatinine ratio Results are shown as means of log-transformed data (antilogged) with 95% confidence estimates in parentheses.
Abbreviation: CT, calcitonin.
Alkaline
Hydroxyproline/creatinine phosphatase ratio of (Table 2) . When the summated calcium drop from 4 to 6 h was plotted for each group a significant dose-response was evident (analysis of variance: P<0.01; Fig. 2 ). As expected, there was a significant correlation between hydroxyproline excretion before the test and the fall in serum calcium in patients given 100 units of subcutaneous calcitonin ( r = 0.7; P = 0.038). No significant correlation was observed, however, at any other dose, since the hypocalcaemic response appeared to be blunted particularly in those patients with the more marked disease activity. In order to explore this further we computed the relationship between initial disease activity and the hypocalcaemic response by bivariate regression in those patients given 100 units of subcutaneous calcitonin. In this way we calculated the expected maximal hypocalcaemic response (E) in the other tests from the initial urinary hydroxyproline. The observed (0) and expected hypocalcaemic responses for each patient were then compared by plotting:
( O -E ) / E When patients were subdivided into 'low' and 'high' boneturnover groups based on their initial hydroxyproline excretion (values for all patients were ranked in increasing order and then divided into two equal groups about the median, i.e. < or > 58 ,umol/mmol of creatinine), there was a significant difference between the hypocalcaemic responses of the patients with low and high turnover when nasal calcitonin was administered (P<0.05; Fig. 3 ). Thus in the high turnover group the observed hypocalcaemic effect of nasal calcitonin was less than expected, but in the To produce an estimate of the bioequivalence of intranasal calcitonin we plotted the mean summated calcium drop from 4 to 6 h for placebo and each dose of subcutaneous calcitonin against the logarithm of the dose used. The curve thus obtained was used to determine the dose of subcutaneous calcitonin that would have induced the fall in serum calcium observed in each patient receiving intranasal calcitonin (summated calcium drop from 4 to 6 h). Four hundred international units of intranasal calcitonin was equivalent to a mean of 29.9 i.u. of subcutaneous calcitonin, but the variation was wide (95% confidence limits 0-1 11.2 i.u.). This suggests a bioequivalence of around 7.5"/0 (95% confidence limits 0-27.8%).
Other effects
After the administration of 100 units of subcutaneous calcitonin there was an increase in the urinary hydroxyproline excretion ( P = 0.049 at 2 h), and this was followed by a significant fall to below starting values from 4 to 6 h (PC0.05). During this period (4-6 h), as with the serum A similar pattern was seen with 10 units of calcitonin (Table 3) . No significant changes in hydroxyproline excretion were observed with either the 1 unit of calcitonin or with placebo. Nasal calcitonin induced a fall in the urinary hydroxyproline excretion that was significant by 3 h ( P = 0.042) and had reached a steady state by 4 h. The cumulative fall from 4 to 6 h (58.4k 14.2 pmol of hydroxyproline/mmol of creatinine) was less than that seen with both 10 and 100 units of subcutaneous calcitonin (75.9f34.2 and 67.2t-29.6 pmol of hydroxyproline/mmol of creatinine. respectively).
The serum activity of alkaline phosphatase did not change significantly throughout the test in any group.
DISCUSSION
In this study we have shown a dose-dependent fall in serum calcium concentration after the administration of subcutaneous calcitonin to patients with Paget's disease of bone. A dose-dependent decrease in serum calcium has not been consistently observed [lo, 21,221 , perhaps due to the failure to match patients for disease activity. Indeed, a major determinant of the hypocalcaemic response to calcitonin in Paget's disease is the degree of disease activity and by matching the treatment groups for disease activity we hoped to reduce the importance of this factor in our assessment.
The major mechanism for an acute fall in serum calcium values is thought to be due to the inhibition of bone resorption [18] and this view is supported by the correlation we noted between the hypocalcaemic response to the larger dose of calcitonin (100 i.u.) and the prevailing rate of bone turnover. Whereas hydroxyproline excretion also fell, it is of interest that a small increase in the hydroxyproline/creatinine excretion ratio was observed in patients given the larger dose of calcitonin (100 i.u.). The mechanism for this is unknown, but small increases have been observed by others, particularly in patients with lower rates of bone resorption [23, 24] . This might suggest that calcitonin actively decreases tubular reabsorption and clearance of hydroxyproline, but a nonrenal effect is also plausible.
Surprisingly, low doses of calcitonin appeared to have acute effects qualitatively similar to those observed with the highest dose used (100 i.u.) which are commonly recommended for the treatment of bone disease. The daily endogenous secretion rate for calcitonin has been estimated at 20 i.u., but this is almost certainly an overestimate [25] . It therefore seems possible that doses such as 10 i.u. might be exerting pharmacological effects. The physiological role of calcitonin in man is still speculative [26] , but the small responses evoked with only 1 unit of calcitonin suggest it may still prove to have a role in extracellular calcium homoeostasis.
In this study 400 units of intranasal calcitonin, b' w e n as a single dose, appeared to have biological effects similar to those observed with the use of subcutaneous calcitonin. The activity of the nasal spray was, however, low, since thc hypocalcaemic effect of 400 units of intranasal calcitonin was similar to that of 10 units given subcutaneously. We did not study any dose-response of nasal calcitonin, but the sub-optimal response of serum calcium suggests a bioequivalence of approximately 7.5%.
It is of particular interest that the response to the intermediate dosc of parcnteral calcitonin ( 1 0 im.) and to the nasal spray differed according to disease activity. Thus whereas maximal effects were observed in patients with the less cxtcnsivc disease activity, in patients with the higher discasc activity the hypocalcaemic effect was incomplete. Since the hypocalcaemic action of calcitonin is primarily rclatcd to osteoclastic inhibition, and this is also the mechanism by which calcitonin induces longterm suppression of disease activity in Paget's disease, it is likcly that at this dosage nasal calcitonin would be unable to provide long-term disease suppression except in patients with mild disease activity (e.g. a urinary hydroxyproline/creatinine ratio < 58 pmol/mmol of creatinine).
Nevertheless the efficacy of small doses of calcitonin suggests that at low rates of bone turnover the nasal spray, even with its low bioequivalence, might be suitable for long-term use in bone disorders associated with lower rates of bone turnover, such as osteoporosis. This ability of small doses of calcitonin to inhibit bone resorption in the presence of moderate increases in bone resorption may explain its apparent efficacy in delaying the bone loss of postmenopausal osteoporosis [27] .
